statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
AS - Asia	1.181
NA - Nord America	1.168
EU - Europa	654
SA - Sud America	245
AF - Africa	10
OC - Oceania	1
Totale	3.259

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	1.132
SG - Singapore	590
HK - Hong Kong	497
BR - Brasile	232
RU - Federazione Russa	228
IT - Italia	220
DE - Germania	65
CN - Cina	36
GB - Regno Unito	25
CA - Canada	24
AT - Austria	18
NL - Olanda	14
IE - Irlanda	13
TR - Turchia	13
FI - Finlandia	12
SE - Svezia	12
LT - Lituania	11
IN - India	9
MX - Messico	9
FR - Francia	8
UA - Ucraina	8
BD - Bangladesh	6
VN - Vietnam	6
EE - Estonia	5
ZA - Sudafrica	5
ES - Italia	4
UZ - Uzbekistan	4
AE - Emirati Arabi Uniti	3
AR - Argentina	3
BE - Belgio	3
CH - Svizzera	3
IQ - Iraq	3
JP - Giappone	3
CL - Cile	2
CO - Colombia	2
IR - Iran	2
KE - Kenya	2
NP - Nepal	2
PL - Polonia	2
VE - Venezuela	2
AM - Armenia	1
AU - Australia	1
BB - Barbados	1
BH - Bahrain	1
BO - Bolivia	1
CI - Costa d'Avorio	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
EC - Ecuador	1
HN - Honduras	1
HU - Ungheria	1
IL - Israele	1
JO - Giordania	1
LB - Libano	1
MA - Marocco	1
PK - Pakistan	1
PY - Paraguay	1
SA - Arabia Saudita	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	3.259

Salva come PNG Salva come JPEG

Città	#
Hong Kong	493
Singapore	324
Boardman	236
Chicago	214
The Dalles	72
Santa Clara	51
Assago	26
Nuremberg	22
São Paulo	22
Los Angeles	21
Milan	18
Munich	18
Ashburn	17
Dublin	13
San Francisco	13
Frankfurt am Main	12
Brooklyn	11
Belo Horizonte	10
Boston	10
London	9
Toronto	9
Vergiate	9
Chandler	8
Düsseldorf	8
New York	8
Stockholm	8
Ankara	7
Moscow	7
Cavaria con Premezzo	6
Fairfield	6
Helsinki	6
Mexico City	6
Porto Alegre	6
Rio de Janeiro	6
Rome	6
Romola	6
Vienna	6
Amsterdam	5
Beijing	5
Campo Grande	5
Chennai	5
Contagem	5
Guidonia Montecelio	5
Ottawa	5
Seattle	5
Secaucus	5
Turku	5
Varese	5
Atlanta	4
Buffalo	4
Houston	4
São José dos Campos	4
Tashkent	4
Brussels	3
Campinas	3
Charlotte	3
Dallas	3
Des Moines	3
Fort Worth	3
Fortaleza	3
Jacksonville	3
Johannesburg	3
Joinville	3
Juiz de Fora	3
Manchester	3
Nyköping	3
Piracicaba	3
Rio Grande	3
Salvador	3
San Jose	3
Tokyo	3
Vancouver	3
Wilmington	3
Zurich	3
Acerra	2
Americana	2
Ann Arbor	2
Annapolis	2
Birigui	2
Bologna	2
Carney	2
Caruaru	2
Erbil	2
Goiânia	2
Hanoi	2
Ibirité	2
Isernia	2
Kryvyi Rih	2
Mandaguari	2
Montreal	2
Mumbai	2
Nairobi	2
Nizhniy Novgorod	2
Osasco	2
Phoenix	2
Portsmouth	2
Princeton	2
Quận Bình Thạnh	2
Rende	2
Ribeirão das Neves	2
Totale	1.920

Salva come PNG Salva come JPEG

Nome	#
AISF position paper on HCV in immunocompromised patients	108
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study	27
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	26
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	25
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	23
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	23
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	22
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	22
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	22
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	22
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	22
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	21
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	21
Longitudinal Assessment of CLL Patients Under Ibrutinib Treatment Reveals Maintained Capacity to Respond to Microenvironmental Stimuli through the Toll-like Receptors	21
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	21
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence	21
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	20
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells	20
NEW PROSPECTS FOR INDUCTION OF ANTI-LYMPHOMA IMMUNITY USING DNA VACCINES EXPRESSING CHEMOKINE-PARTICLES	20
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	20
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	20
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	19
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	19
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	19
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	19
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	19
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	19
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	19
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	19
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis	19
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	19
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	19
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	19
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial	18
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	18
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	18
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	18
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)	18
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation	18
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	18
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	18
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	18
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	18
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells	18
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	17
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	17
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	17
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy	17
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	17
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results	17
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells	17
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	17
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)	17
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells	17
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	17
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy	17
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells	16
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL)	16
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	16
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID	16
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)	16
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience	16
Magic pills: new oral drugs to treat chronic lymphocytic leukemia	16
Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study	16
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification	16
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL	16
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights	16
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells	16
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia	16
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients	16
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	16
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: Multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials	15
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	15
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	15
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response	15
Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life	15
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22	15
Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?	15
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma	15
Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22	15
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL)	15
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE	15
LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA	15
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	15
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study	15
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	15
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method	15
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia	15
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting	15
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study	15
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target	15
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	15
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group	15
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia	15
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA	15
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia	15
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease	15
IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI 0) INDEPENDENT OF UNMUTATED STATUS	15
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial	15
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab	15
Totale	1.852

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	27.796
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	27.796

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	33	4	1	9	1	3	2	0	4	2	2	1	4
2021/2022	7	0	0	2	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	3.409	239	34	868	158	181	118	136	111	283	200	222	859
Totale													3.499